Journals / Kocaeli Tıp Dergisi / 2021 / Cilt: 10 - Sayı: 2

Short And Mid Term Results Of Transcatheter Aortic Valve Implantation: A Single-Center Experience

Transkateter Aort Kapak Replasmanı Kısa ve Orta Dönem Sonuçları: Tek Merkez Deneyimi

Pages
131–139
Publication Date
2022-11-06
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

DISCUSSION AND CONCLUSION: TAVR is an appropriate treatment option with low mortality risk in patients who cannot be operated due to high surgical risk.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:INTRODUCTION: Patients with severe aortic stenosis and symptomatic should be treated surgically.
📊
Key Findings & Data:Because of advanced age and comorbidities, 30% of patients cannot be treated.
💡
Conclusion & Impact:DISCUSSION AND CONCLUSION: TAVR is an appropriate treatment option with low mortality risk in patients who cannot be operated due to high surgical risk.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

INTRODUCTION: Patients with severe aortic stenosis and symptomatic should be treated surgically. Because of advanced age and comorbidities, 30% of patients cannot be treated. For this purpose transcatheter aortic valve replacement (TAVR) procedure has been developed. The purpose of our study is to analyze real life results of patients who underwent TAVR. METHODS: 136 patients were analyzed retrospectively. Primary endpoint was perioperative mortality (POM), secondary endpoints were major adverse cardiovascular and cerebrovascular events(MACCE), developed during the6-month post-procedure period and permanent pacemaker (PPM) requirement in postoperative period. RESULTS: In patients, developed POM; PPM, transfusion and intubation requirements were higher, postoperative hemoglobin was lower, postoperative BUN, leukocyte and 48th hour creatinine were higher. PPM requirement was higher in women and patients with left bundle branch block on ECG after procedure. In patients who developed MACCE, presence of chronic obstructive pulmonary disease, intubation and transfusion requirement, preoperative CRP and postoperative CRP and leukocyte were higher. In multivariate regression analyzes, independent risk factors of POM were transfusion and PPM requirement, MACCE risk factors were intubation and transfusion requirement, and PPM risk factor was female gender. DISCUSSION AND CONCLUSION: TAVR is an appropriate treatment option with low mortality risk in patients who cannot be operated due to high surgical risk.

Özet

GİRİŞ ve AMAÇ: Ciddi aort darlığı olan semptomatik hastalar cerrahi olarak tedavi edilmelidirler. İleri yaş ve komorbiditeler sebebi ile hastaların %30’u tedavi edilememektedir. Bu amaçla transkateter aort kapak replasmanı (TAVR) geliştirilmiştir. Çalışmamızın amacı TAVR yapılan hastaların gerçek yaşam sonuçlarını yayınlamaktır. YÖNTEM ve GEREÇLER: TAVR işlemi yapılan 136 hasta retrospektif incelenmiştir. Primer sonlanım noktası perioperatif mortalite (POM), sekonder sonlanımlar postoperatif 6 ay içerisinde gelişen major adverse serebrovasküler ve kardiyovasküler olaylar (MASKO) ve postoperatif kalıcı kalp pili (KKP) ihtiyacı olarak belirlenmiştir. BULGULAR: POM gelişen hastalarda KKP, entübasyon ve kan transfüzyonu daha fazla, postoperatif hemoglobin daha düşük, postoperatif BUN, lökosit ve 48. saat kreatinin daha yüksek bulunmuştur. KKP ihtiyacı kadınlarda ve işlem sonrasında sol dal bloğu gelişen hastalarda daha fazla olmuştur. MASKO gelişen hastalarda kronik obstrüktif akciğer hastalığı, entübasyon ve transfüzyon ihtiyacı daha fazla, preoperatif CRP ile postoperatif CRP ve lökosit daha yüksek bulunmuştur. POM’ nin bağımsız risk faktörleri işlem sonrasında transfüzyon ve KKP ihtiyacı gelişmesi, MASKO risk faktörleri entübasyon ve transfüzyon ihtiyacı olması, KKP için risk faktörü kadın cinsiyet olmuştur. TARTIŞMA ve SONUÇ: Transkateter aort kapak replasmanı yüksek cerrahi risk nedeni ile operasyon yapılamayan hastalarda düşük mortalite oranı ile uygun bir tedavi seçeneğidir.

🔖

Cite This Article

KILINÇ, A. Y., DEMİR, F. A., ALTEKİN, R. E., DEMİR, İ., ONAÇ, M., SAYDAM, G. (2022). Short And Mid Term Results Of Transcatheter Aortic Valve Implantation: A Single-Center Experience. Kocaeli Tıp Dergisi, Cilt: 10 - Sayı: 2, 131–139. https://ajindex.com/articles/652941

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (11)

  1. Passik CS, Ackerman DM, Pluth JR. Temporal changes in the causes of aortic stenosis: Asurgical pathological study of 646 cases. Mayo Clin Proc 1987; 62: 119-23.
  2. Townsend CM, Beauchamp RD, et al. Sabiston Textbook of Surgery. 18th ed. Saunders 2008; 1841-4. 3. 2017 ESC/EACTS Guidelines for the management of valvular heart disease, European Heart Journal 2017; 38: 2739-86. doi:10.1093/eurheartj/ehx391
  3. Bouma BJ, van den Brink RBA, van der Meulen JHP, et al. To operate or not on elderly patients with aortic stenosis: the decision and its consequences. Heart 1999; 82: 143-8.
  4. Iung B, Cachier A, Baron G, et al. Decision-making in elderly patients with severe aortic stenosis: why are so many denied surgery? Eur Heart J 2005; 26: 2714-20.
  5. Cribier A, Eltchaninoff H, Bash A, et al. Percutaneous Transcatheter Implantation of an Aortic Valve Prosthesis for Calcific Aortic Stenosis. Circulation 2002; 106: 3006-8.
  6. Yücel G, Paker T, Akçevin A, et al. Transcatheter aortic valve implantation: the first applications and early results in Turkey. [Article in Turkish] Turk Kardiyol Dern Ars 2010; 38: 258-63
  7. Kappetein AP, Head SJ, Genereux P, et al. Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus document, European Heart Journal 2012; 33: 2403-18. doi:10.1093/eurheartj/ehs255
  8. Himbert D, Descoutures F, Al-Attar N, et al. Results of transfemoral or transapical aortic valve implantation following a uniform assessment in high-risk patients with aortic stenosis. J Am Coll Cardiol 2009; 54: 303-11.
  9. Webb JG, Altwegg L, et al. Transcatheter aortic valve implantation: impact on clinical and valve-related outcomes. Circulation 2009; 119: 3009-16.
  10. Leon MB, Smith CR, Mack M, et al, for the PARTNER Trial Investigators, Transcatheter Aortic-Valve Implantation for Aortic Stenosis in Patients Who Cannot Undergo Surgery. N Engl J Med 2010; 363: 1597-607
  11. BajrangeeA, Coughlan JJ, Teehan S, et alEarly and mid-term outcomes after transcatheter aortic valve implantation (TAVI) in Ireland, http://dx.doi.org/10.1016/j.ijcha.2017.06.